Primary Care Docs Don't Know Chemo Side Effects, Says Survey

Results of a new survey presented in advance of the American Society of Clinical Oncology meeting suggests that most primary care doctors are ignorant about the long-term dangers and side-effects of chemotherapy.

Dr. Larissa Nekhlyudov of Harvard Medical School and colleagues conducted a survey of 1,072 primary care doctors and 1,130 cancer specialists by mail, asking them which of five side effects they had seen most frequently in their practices or seen reported for each of four widely used chemotherapy drugs:

- Doxorubicin
- Paclitaxel
- Oxaliplatin
- Cyclophosphamide.

What they found was that just six percent of primary care physicians knew the main long term side effects of all four of the drugs, versus sixty-five percent of oncologists.

While primary care doctors may not be expected to know the main side effects of chemotherapy, the problem is that 12 million US cancer survivors are receiving follow-up care from these primary care doctors, and they could be missing the nerve damage or the cardiovascular or pulmonary problems, or even secondary cancers, associated with chemotherapy.

Source: ASCO

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap